Last Updated: August 3, 2026

GALLIUM GA 68 GOZETOTIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Gallium Ga 68 Gozetotide patents expire, and when can generic versions of Gallium Ga 68 Gozetotide launch?

Gallium Ga 68 Gozetotide is a drug marketed by Radiomedix, Univ Ca Los Angeles, and Univ Of Ca San Fran. and is included in three NDAs.

The generic ingredient in GALLIUM GA 68 GOZETOTIDE is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gallium Ga 68 Gozetotide

A generic version of GALLIUM GA 68 GOZETOTIDE was approved as gallium ga-68 gozetotide by IONETIX on May 14^th, 2026.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for GALLIUM GA 68 GOZETOTIDE?
What are the global sales for GALLIUM GA 68 GOZETOTIDE?
What is Average Wholesale Price for GALLIUM GA 68 GOZETOTIDE?

Summary for GALLIUM GA 68 GOZETOTIDE

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for GALLIUM GA 68 GOZETOTIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Radiomedix	GALLIUM GA 68 GOZETOTIDE	gallium ga-68 gozetotide	SOLUTION;INTRAVENOUS	216410-001	Jun 8, 2026	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Univ Ca Los Angeles	GALLIUM GA 68 GOZETOTIDE	gallium ga-68 gozetotide	SOLUTION;INTRAVENOUS	212642-001	Dec 1, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Univ Of Ca San Fran	GALLIUM GA 68 GOZETOTIDE	gallium ga-68 gozetotide	SOLUTION;INTRAVENOUS	212643-001	Dec 1, 2020	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.